Verve Therapeutics Profit Margin

Verve Therapeutics (VERV) currently reports a profit margin of -303.64% as of March 2025. That compares with -1226.43% in the prior-year period — up 75.2% year over year. That is below the Healthcare sector average of 14.41%. Use the charts on this page to explore Verve Therapeutics's profit margin history and peer comparisons.

Verve Therapeutics's profit margin increased from -1226.43% to -303.64% — a 75.2% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Verve Therapeutics's profit margin of -303.64% is lower than the Healthcare sector average of 14.41%. That is roughly 2206.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Verve Therapeutics's current -303.64% should be judged against Healthcare norms (sector average: 14.41%) and against VERV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -303.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.41%. From there, open related valuation or income-statement pages for Verve Therapeutics, and consider following VERV for alerts when major investors trade the stock.